CD 19×CD3 specific polypeptides and uses thereof
AssigneeMicromet AG
InventorsBernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
Life of this patent
Estimating the term…
Loading patent…
AssigneeMicromet AG
InventorsBernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
Estimating the term…
Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
A single-chain multi-functional polypeptide comprising
A composition comprising a single-chain multi-functional polypeptide comprising:
A method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells comprising administering to a human afflicted with said malignancies, diseases or depletion, an effective amount of
Dependencies are inferred from the claim text.